1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

 
• By Jo Shorthouse

Roche’s investigational non-small cell lung cancer candidate entrectinib has shown to reduce tumors in people with ROS1-positive NSCLC, including those whose disease had spread to the central nervous system, differentiating it from potential competitors.

Light bulb

Results from the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials show that Roche's entrectinib shrank tumors in 77% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Entrectinib, a tyrosine kinase inhibitor being developed for tumors that harbor NTRK or ROS1 fusions, also demonstrated a durable response of more than two years. Entrectinib was shown to shrink...

More from Anticancer

More from Therapy Areas